The European Conference on Fungal Genetics (ECFG 2025) gathered the leading fungal biology teams from across the world. Although primarily a genetics meeting, several abstracts offered direct clinical relevance for people living with aspergillosis or those working in the field.
The research covered here focuses on:
-
Aspergillus fumigatus
-
mechanisms of disease
-
resistance to antifungals
-
emerging antifungal treatments
-
environmental drivers of disease
-
insights relevant to CPA, ABPA, SAFS, bronchiectasis and invasive aspergillosis
Summary of Key Themes
1. Aspergillus genetic diversity is much greater than assumed
Pangenome work showed A. fumigatus strains possess different virulence genes and resistance traits. This may explain differences in how patients respond to infection and medication.
2. Environmental azole resistance continues to rise
Multiple abstracts confirmed that resistant strips often originate outdoors, shaped by climate, fungicides, soil chemistry, and climate change.
3. Promising new antifungals are advancing
Manogepix shows excellent activity against resistant strains, while several early-stage compounds (such as G-quadruplex ligands) represent brand-new modes of action.
4. Insights into virulence, persistence and treatment failure
Studies on hyphal fusion, echinocandin tolerance, and hypoxia adaptation shed light on chronic and resistant infections.
5. Improved tools accelerate antifungal discovery
CRISPR and genus-wide sequencing speed up the search for new drug targets and better diagnostics.
ECFG 2025 — Table of All Aspergillus / Aspergillosis / Antifungal-Relevant Abstracts
| ID | Title | Lead Author / Presenter | Institution | Category | Why It Matters |
|---|---|---|---|---|---|
| WS1.19 | Reference pangenomes for A. fumigatus | Marion Perrier | Friedrich Schiller University, Jena | Genomics / Evolution | Reveals hidden genetic diversity linked to virulence and resistance. |
| WS1.20 | Antifungal modes of action of G-quadruplex ligands | Isabelle Storer | University of East Anglia | New antifungal mechanisms | Suggests a brand-new antifungal class targeting fungal DNA structures. |
| WP1.2 | NL1 as anti-virulence compound | Jorge Amich | ISCIII, Spain | Virulence / Therapeutics | May reduce disease severity without relying on killing the fungus. |
| WP1.6 | Ace2 and RAM pathway regulation | Devi N. J. Bale | — | Pathogenesis | Controls tissue invasion, morphology and possibly drug sensitivity. |
| WP1.8 | Hyphal fusion and multi-drug resistant heterokaryons | Michael Bottery | University of Manchester | Resistance mechanisms | Shows resistance traits may spread between strains via fusion. |
| WP1.10 | Manogepix activity against A. fumigatus | Sean Brazil | Trinity College Dublin | New antifungals | Strong activity including against resistant strains and biofilms. |
| WP1.14 | ZfpA and echinocandin tolerance | Dante Calise | University of Wisconsin | Echinocandin tolerance | Explains how fungi sometimes survive caspofungin and related drugs. |
| WP1.16 | Genetic background of azole-resistant A. fumigatus | Saioa Cendón-Sánchez | University of the Basque Country | Environmental resistance | Confirms resistant genotypes circulate between the environment and patients. |
| WP1.18 | Genus-wide sequencing of Aspergillus | Ronald P. de Vries | Westerdijk Institute | Evolution / Pathogenicity | Identifies traits making some species pathogenic to humans. |
| WP1.22 | Climate, soil & fungicide impacts on Aspergillus | Thomas Easter | University of Manchester | Environmental epidemiology | Links climate change and fungicides to rising azole resistance. |
| WP1.32 | Multiplex CRISPR to accelerate antifungal research | Fabio Gsaller | — | Research tools | Speeds identification of resistance pathways and drug targets. |
| WP1.42 | Hypoxia-driven adaptations in A. fumigatus | Olaf Kniemeyer | — | Pathogenesis | Explains persistence of A. fumigatus in low-oxygen lung cavities (CPA). |
Detailed Clinical Relevance of the Findings
1. Rising environmental resistance
Azole-resistant A. fumigatus continues to emerge in agricultural and urban settings. Resistant spores are carried in air and soil, meaning people inhale them in daily life. This is especially relevant to those with CPA, ABPA, bronchiectasis and immunosuppression, who are more vulnerable.
Why it matters:
Resistant strains are a growing cause of treatment failure.
2. New antifungal treatments are progressing
Manogepix shows potent activity against resistant Aspergillus and biofilms, key in difficult-to-treat CPA and invasive aspergillosis.
G-quadruplex ligands and NL1 represent early steps toward new antifungal classes, extremely important after two decades of limited drug options.
3. Virulence and survival mechanisms explain persistent disease
Hypoxia adaptation (low-oxygen survival) helps explain why Aspergillus persists in lung cavities.
Hyphal fusion may allow rapid spread of resistance traits.
Echinocandin tolerance mechanisms (ZfpA) reveal why some invasive cases fail to respond.
Why it matters:
These insights help clinicians anticipate treatment difficulties and inform research for new therapies.
4. Better genomic tools support faster discovery
Multiplex CRISPR and pangenomic databases allow scientists to uncover gene functions much faster. This shortens the path to new antifungal development and improves understanding of how resistance evolves.
Conclusion
ECFG 2025 provides important clues about why Aspergillus disease is so persistent, why azole resistance is increasing, and how new antifungal drugs may overcome today’s challenges. It also reinforces that environmental drivers — including fungicide use and climate factors — are a major part of the problem.
For patients, clinicians, and researchers, these findings highlight a rapidly evolving landscape in aspergillosis research, with promising signs of future treatment improvements.
Latest News posts
News archive